Anti-LRPPRC/GP130 antibody

• IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LRPPRC/GP130 antibody (AB205022)

Immunohistochemical analysis of formalin-fixed, paraffin-embedded human ovarian carcinoma tissue labeling LRPPRC/GP130 with ab205022 at a 1/1000 dilution.

• IP

Supplier Data

Immunoprecipitation - Anti-LRPPRC/GP130 antibody (AB205022)

Detection of human LRPPRC/GP130 by immunoprecipitation of whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HEK293T cells prepared using NETN lysis buffer.

Lane 1 : Rabbit polyclonal to LRPPRC/GP130 (ab205022) at 6 μg/mg lysate

Lane 2 : Control IgG

Detection : Chemiluminescence with an exposure time of 30 seconds. ab70386 was used at 0.4 ug/mL for Western blot.

All lanes:

Immunoprecipitation - Anti-LRPPRC/GP130 antibody (ab205022)

Predicted band size: 158 kDa

false

• WB

Supplier Data

Western blot - Anti-LRPPRC/GP130 antibody (AB205022)

All lanes:

Western blot - Anti-LRPPRC/GP130 antibody (ab205022) at 0.1 µg/mL

Lane 1:

HeLa whole cell lysate at 50 µg

Lane 2:

293T whole cell lysate at 50 µg

Lane 3:

Jurkat whole cell lysate at 50 µg

Predicted band size: 158 kDa

true

Exposure time: 3min

• WB

CiteAb

Western blot - Anti-LRPPRC/GP130 antibody (AB205022)

LRPPRC/GP130 western blot using anti-LRPPRC/GP130 antibody ab205022. Publication image and figure legend from Xu, X., Ma, C., et al., 2019, Front Pharmacol, PubMed 31040785.

ab205022 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab205022 please see the product overview.

ZEB1-AS1 regulates mRNA stability of NOD2 via recruiting LRPPRC. (A) LRPPRC was silenced by specific siRNAs at both transcript (down panel) and protein (upper panel) levels, **P < 0.01 (Mann–Whitney U-test). (B) NOD2 expression was detected in HUVECs overexpressed with ZEB1-AS1 and/or silenced with LRPPRC, *P < 0.05 (Mann–Whitney U-test). (C) HUVECs lysates were incubated with in vitro synthesized, biotin-labeled control LacZ DNA probes or DNA probes against ZEB1-AS1 for the biotinylated oligonucleotide pulldown assay. The precipitates from the pulldown were analyzed by qRT-PCR to detect the interacting mRNAs. **P < 0.01 (Mann–Whitney U-test) compared to respective LacZ probes. (D) RIP was performed using anti-LRPPRC and control IgG antibodies, followed by qRT-PCR to examine the enrichment of NOD2 and U6. U6 served as negative controls. **P < 0.01 (Mann–Whitney U-test) compared to respective IgG controls. (E) HUVECs expressing si-ZEB1-AS1#2 or si-LRPPRC were treated with actinomycin D (5 μg/mL) for the indicated periods of time. *P < 0.05 (Mann–Whitney U-test) compared to si-NC group (F). HUVECs expressing si-NC, or p-ZEB1-AS1, or p-ZEB1-AS1 + si-LRPPRC were treated with actinomycin D (5 μg/mL) for the indicated periods of time. Total RNA was purified and then analyzed using qRT-PCR to examine the mRNA half-life of NOD2. *P < 0.05 (Mann–Whitney U-test) compared to si-NC group, and #P < 0.05 (Mann–Whitney U-test) compared to p-ZEB1-AS1 group.

false